Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €454.45 EUR
Change Today -10.84 / -2.33%
Volume 20.0
RGO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 2:24 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

regeneron pharmaceuticals (RGO) Snapshot

Open
€471.75
Previous Close
€465.29
Day High
€471.75
Day Low
€454.45
52 Week High
06/8/15 - €491.00
52 Week Low
06/30/14 - €200.50
Market Cap
46.5B
Average Volume 10 Days
122.7
EPS TTM
--
Shares Outstanding
101.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENERON PHARMACEUTICALS (RGO)

regeneron pharmaceuticals (RGO) Details

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company’s trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

3,066 Employees
Last Reported Date: 05/7/15
Founded in 1988

regeneron pharmaceuticals (RGO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $3.2M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $905.0K
Chief Scientific Officer, Director, Member of...
Total Annual Compensation: $2.7M
Executive Vice President of Research and Deve...
Total Annual Compensation: $1.0M
Senior Vice President of Commercial
Total Annual Compensation: $843.1K
Compensation as of Fiscal Year 2014.

regeneron pharmaceuticals (RGO) Key Developments

Regeneron Pharmaceuticals, Inc. Approves Amendment to Certificate of Incorporation

Regeneron Pharmaceuticals, Inc. announced that at the annual meeting of shareholders held on June 12, 2015 approved an amendment to the company's certificate of incorporation to increase the number of authorized shares of capital stock and common stock.

Regeneron Pharmaceuticals Inc. Announces FDA Approval of Sanofi and Regeneron's Praluent(R) (Alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to three (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.

Regeneron Pharmaceuticals Inc. Announces Updates on Phase 3 Study of Sarilumab

Regeneron Pharmaceuticals Inc. announced that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo. The study, called SARIL-RA-TARGET, evaluated the efficacy and safety of two subcutaneous sarilumab doses versus placebo, added to non-biologic disease modifying anti-rheumatic drugs (DMARD) therapy in RA patients who were inadequate responders to or intolerant of TNF-alpha inhibitors (TNF-IR). The SARIL-RA-TARGET trial enrolled 546 TNF-IR patients who were randomized to one of three treatment groups self-administered subcutaneously (SC) every other week (Q2W): sarilumab 200 milligrams (mg), sarilumab 150 mg, or placebo, in addition to DMARD therapy. Both sarilumab groups showed clinically relevant and statistically significant improvements compared to the placebo group in both co-primary endpoints (p greater than 0.001): Improvement in signs and symptoms of RA at 24 weeks, as measured by the American College of Rheumatology score of 20% improvement (ACR20), were as follows: 61% in the sarilumab 200 mg group; 56% in the sarilumab 150 mg group; and 34% in the placebo group, all in combination with DMARD therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGO:GR €454.45 EUR -10.84

RGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $132.31 USD -2.53
Incyte Corp $100.82 USD -3.23
Kyowa Hakko Kirin Co Ltd ¥1,612 JPY -57.00
UCB SA €65.35 EUR -1.09
Vertex Pharmaceuticals Inc $122.03 USD -4.84
View Industry Companies
 

Industry Analysis

RGO

Industry Average

Valuation RGO Industry Range
Price/Earnings 100.0x
Price/Sales 17.4x
Price/Book 17.9x
Price/Cash Flow 151.1x
TEV/Sales 17.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit www.regeneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.